Calcitonin: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: SC/IM, nasal *Common Trade Names: ==Adult Dosing== *Hypercalcemia: 4 IU/kg SC/IM q12hr ==Pediatric...") |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 66: | Line 66: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:Endocrinology]] [[Category:FEN]] | ||
Latest revision as of 21:41, 19 September 2019
Administration
- Type:
- Dosage Forms:
- Routes of Administration: SC/IM, nasal
- Common Trade Names:
Adult Dosing
- Hypercalcemia: 4 IU/kg SC/IM q12hr
Pediatric Dosing
Safety/efficacy not established
Special Populations
Pregnancy Rating
- C
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Malignancy risk increased in longterm use
Common
- Rhinitis, epistaxis (intranasal)
- Arthralgia, back pain
- Injection site reaction
- Nausea, abdominal pain, decreased appetite
- Headache
- Flushing
- Allergic reaction
- Edema of feet
- Eye pain
- Subjective fever
- Nocturia
- Salty taste
Pharmacology
- Half-life: 43min[1]
- Metabolism: Renal
- Excretion: Urinary
Mechanism of Action
- Inhibits osteoclastic bone resorption, decreases serum calcium, and increases renal excretion of phosphate, calcium, sodium magnesium and potassium by decreasing tubular reabsorption[2]